Welcome to our dedicated page for Inflarx news (Ticker: IFRX), a resource for investors and traders seeking the latest updates and insights on Inflarx stock.
InflaRx N.V. develops anti-inflammatory therapeutics that target the complement system through proprietary anti-C5a and anti-C5aR technologies. Its lead program, izicopan, is an orally administered small-molecule inhibitor of C5a-induced signaling via the C5a receptor, and vilobelimab is an intravenously delivered anti-C5a monoclonal antibody that selectively binds free C5a.
Company news commonly covers izicopan clinical-development strategy, preclinical pharmacology data, complement-mediated inflammatory disease programs, financial results, ordinary-share financings, Nasdaq listing compliance, annual meeting matters and investor communications. Updates also address the company’s operating group, which includes wholly owned subsidiaries in Germany and the United States.
InflaRx (Nasdaq: IFRX) announced a late-breaking oral presentation of Phase 3 vilobelimab results in pyoderma gangrenosum at the 2026 American Academy of Dermatology Annual Meeting in Denver, March 27-31, 2026.
The oral session is scheduled for March 28, 2026, 2:24-2:36 PM MT, presenter Benjamin Kaffenberger, MD. The company also highlights its izicopan program and anti-C5a/C5aR platform.
InflaRx (Nasdaq: IFRX) will report fourth quarter and full year 2025 results on March 19, 2026 before the market opens; no conference call is planned.
The company is developing izicopan (INF904), an oral C5aR inhibitor, and vilobelimab, an IV anti-C5a antibody, and maintains offices in Jena, Munich and Ann Arbor.
InflaRx (Nasdaq: IFRX) will participate in the Leerink Partners Global Healthcare Conference in Miami, March 8-11, 2026, with a fireside chat on March 9 at 9:20 AM ET and one-on-one investor meetings the same day.
Live streaming and replay of the fireside chat will be available via a company link; investor relations contacts are provided for meeting requests.
InflaRx (Nasdaq: IFRX) will participate in investor conferences in February 2026, offering live presentations and one-on-one meetings. Key appearances include a fireside chat at the Guggenheim Biotech Summit on Feb 11, 2026 at 11:30 AM ET and a virtual presentation at Oppenheimer on Feb 25, 2026 at 8:40 AM ET. Replay links and details for one-on-one meetings are available from the company. The release also summarizes InflaRx's lead programs, izicopan and vilobelimab, and corporate locations in Germany and the U.S.
InflaRx (Nasdaq: IFRX) is refocusing resources on its oral C5aR inhibitor izicopan, aiming for Phase 2b readiness in hidradenitis suppurativa (HS) and broader inflammation & immunology (I&I) indications. The company is initiating a PK bridging study in China in 2026 to enable expedited PoC studies and is pursuing partner discussions to accelerate development. InflaRx is executing an ~30% workforce reduction, expects a one-time charge of ~$7 million, and says the actions extend its cash runway to mid-2027. A virtual Capital Markets Day is planned for spring 2026.
InflaRx (Nasdaq: IFRX) provided updated analyses from its terminated Phase 3 study of vilobelimab in ulcerative pyoderma gangrenosum (PG). The trial was stopped early for futility after enrolling 54 patients (30 completed 6 months). The prespecified primary endpoint (complete target ulcer closure on two consecutive visits) favored vilobelimab 20.8% vs placebo 16.7% (p=NS). Post-hoc analyses showed statistically significant reductions in target ulcer volume: MMRM percent change overall -45.4% (p=0.0428) and weekly differences from Week 14 to 26 (e.g., Week 26 -63.2%, p=0.0122); ANCOVAs for volume and area were p=0.0111 and p=0.0072. Safety was generally well tolerated with similar serious related TEAEs (6.3% vs 4.5%). InflaRx plans FDA discussions and expects future PG work would require a partner.
InflaRx (Nasdaq: IFRX) announced the World Health Organization has granted the international nonproprietary name izicopan for its oral C5aR inhibitor formerly known as INF904; the name will be published in the WHO recommended INN list.
Izicopan has shown tolerability in first‑in‑human single doses (3–240 mg) and multiple doses (30 mg once daily to 90 mg twice daily), pharmacokinetic/pharmacodynamic support with a ≥90% blockade of C5a‑induced neutrophil activation over 14 days, and topline Phase 2a signals of clinical activity in hidradenitis suppurativa and chronic spontaneous urticaria.
InflaRx (Nasdaq: IFRX) reported positive topline Phase 2a results for oral C5aR inhibitor INF904 in hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU) on Nov 10, 2025. Data from 29 HS and 30 CSU patients showed rapid reductions in lesion counts and symptoms over 4 weeks with durable effects at Week 8.
Key 4-week signals: HiSCR50 28% (all doses), HiSCR50 Week 8 44% (n=25); AN change −5.1 (all doses); dT100 29%; NRS30 pain response 66%; CSU UAS7 change −10.4 (all doses) and −15.4 in severe CSU (60 mg). No serious adverse events reported. Company targets Phase 2b initiation in HS in 2026 and continues partner discussions.
InflaRx (Nasdaq: IFRX) expects to report topline Phase 2a clinical data for oral C5aR inhibitor INF904 in hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU) in a pre-market press release on November 10, 2025.
The company will host a webcast and slide presentation on November 10, 2025 at 8:00 AM EST / 2:00 PM CET and also expects to publish third quarter 2025 financial results via Form 6-K the same day pre-market.
InflaRx (Nasdaq: IFRX) will participate in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference in Boston, MA from November 10–12, 2025. The company will appear in a fireside chat on November 11 at 2:30 PM ET and will hold one-on-one investor meetings the same day. A live stream and replay link for the fireside chat will be provided.
InflaRx is a biopharmaceutical company focused on anti-inflammatory therapeutics that target the complement system, developing vilobelimab (intravenous anti-C5a antibody) and INF904 (oral C5a receptor inhibitor). The company has offices in Jena and Munich, Germany, and Ann Arbor, MI.